A literature search of gene candidates that might mitigate CAG repeat length within individual HD patients was unrevealing, although a therapeutic effect of downregulating the HDL2 gene JPH3 [23] cannot be fully excluded at this point, and intergenerational expansion might potentially be addressed by downregulating OGG1 [24] or MSH2, MSH3, and PMS2 [25], but these are highly speculative considerations. This evidence concerns the gene JPH3 and Huntington disease.